This round is no longer accepting investments, but hundreds just like it are live now.

Log In


Next generation, cell-based liquid biopsy

StrandSmart is developing a next-generation liquid biopsy (blood) test to enable precision medicine, or the ability to identify the biological driver of a tumor, allowing us to better match the right drug to the individual patient. We are pre-revenue, and are in development, working with academics and pharma to further validate our technology so that we can launch our blood tests to oncologists, giving them the tools to help improve and extend patients’ lives.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

$35,354.71 Raised

Reasons to Invest

  • Utilizing liquid biopsies for precision medicine is already a $4B market and is  estimated to grow to $10B by the end of the decade.

  • Current technologies serving the market rely only on the DNA from tumors to drive their test results and drug prediction. StrandSmart leverages the tumor cell itself, where we can analyze and characterize the DNA, RNA, and proteins to provide a 360 view of the biologic drivers of the tumor, enabling us to develop the most accurate and comprehensive test on the market.

  • Founded in 2017, we already have lab operations in Columbus, Ohio, and are backed by a management team with 8+ venture exits. Most importantly, three of the cofounders launched the first and only FDA-approved liquid biopsy CTC test.



The future of liquid biopsy

Cancer sometimes happens so fast, it often leaves people feeling helpless in their search for solutions. That’s why at StrandSmart - instead of chasing cancer, we aim to get ahead of it,  stopping it in its tracks before it makes its next move. The Company is currently pre-revenue and in the development stage.

This is now possible with technologies such as single-cell sequencing, which allows us to read the signals expressed by millions of cells at once from a given blood sample.

As a next-generation cell-based liquid biopsy company, we focus on profiling live tumor cells to guide therapy selection, patient monitoring, and therapeutic discovery & development. This is all to better help cancer patients on their road to recovery.

The Problem & Our solution

Oncologists are limited in determining how cancer patients will respond to certain treatments. Our live cell characterization provides additional information, which can enable improved decision making.

90% of cancer deaths are due to treatment failure, as cancer is a moving target that changes and evolves (source).

Liquid biopsy tests on the market today can only identify known cancer mutations - which is only about 10% of all cancers (source).

StrandSmart alerts physicians of these mutations so they can respond with alternative interventions - that we believe can lead to better outcomes. StrandSmart can extract the same mutation data as other, and in addition augment the information by adding transcriptomic, and proteomic data. The 360 degree view of cancer  will predict whether a patient will respond to a drug for a much broader patient population (source). By keeping cells alive after extracting them from a blood sample, we equip oncologists and drug developers with the information needed to get the best possible outcomes for patients.

In addition, by keeping cells alive after extracting them from a blood sample, we equip oncologists and drug developers with the information needed to get the best possible outcomes for patients.

We generate revenue by selling lab tests to biotech and pharmaceutical companies that are developing cancer therapies (Research Market) and oncologists who are treating cancer patients (Cancer diagnostics).


The liquid biopsy market is a nascent industry that is experiencing rapid growth in revenue 

That’s because, in the US alone, there are …

Sources:, Cancer.orgCancer.orgVerzenioKomenZero Cancer

We are initially targeting the post-diagnosis oncology market. Our first tests are for metastatic lung, breast, and prostate cancer patients. 

So far, these markets have had to rely on a limited amount of information from the sequencing of DNA for mutations only (source). With that, we believe the timing for StrandSmart is critical. Not only have we overcome the limitations of predecessor technologies for capturing Circulating-Tumor-Cells (CTCs), but the advent of single-cell sequencing technologies enables us to fully exploit them and unload the cargo of information they carry to improve outcomes.   

Here’s a look at our progress to date:



Our vision is a world where cancer is no longer a terminal disease

We think cancer should be managed as a chronic disease that doesn’t interfere with the quality of life or life expectancy.  With that, we want to make personalized cancer treatment accessible to everyone, and at the same time, accelerate the ability of the drug development community to develop new treatments to address all cancer diseases.  

Over the next few years, we aim to…

The advent of genomics and sequencing technology over the last 10 years has already changed how we view and treat cancer with an understanding of DNA and cancer mutations.

StrandSmart sees itself as the driver of the next wave of this progress - all by putting comprehensive data of an individual patient’s cancer in the hands of the oncologists and drug developers battling the disease on the front lines. Invest in our mission today!

Code View



StrandSmart is developing a next-generation liquid biopsy (blood) test to enable precision medicine, or the ability to identify the biological driver of a tumor, allowing us to better match the right drug to the individual patient. We are pre-revenue, and are in development, working with academics and pharma to further validate our technology so that we can launch our blood tests to oncologists, giving them the tools to help improve and extend patients’ lives.


Adrianna Davies
Adrianna Davies
Founder & CEO

Adrianna is a serial life science entrepreneur with a track record of creating value for early-stage technology assets. Adrianna is passionate about solving big problems in healthcare, and her thesis is that prevention is the smartest approach. Adrianna is CEO and cofounder of StrandSmart, a seed-stage startup based in San Francisco, developing a liquid biopsy platform to bridge the gap from cancer detection to true personalized medicine with a simple lab test. StrandSmart is backed by Stanford StartX Med, Formic Ventures, Exxclaim Capital and a number of experienced and exited angel investors. Previously she was at Y-Combinator backed Qurasense Inc., a startup developing menstrual pads to monitor women’s health non-invasively. Before that she founded Sparkup Inc. a platform to accelerate technology transfer from universities to life science companies which was acquired in 2015. She holds her degree from McGill University where she played on both the Varsity soccer and rugby teams. She speaks English, Portuguese, French, Spanish, and Investor. In her time recovering from delivering outcomes for investors, you can find her shredding on some kind of board: surf, snow, kite, or skate.

John Park MD
John Park MD
Chief Scientific Officer

Dr. John W. Park is an oncologist who specializes in breast cancer treatment and research. In his laboratory, Park works to develop novel technologies for studying and treating cancer. His research includes investigating new forms of immunotherapy such as immunoliposomes (antibodies paired with vesicles similar to human cell membranes) and vaccines that target cancer cells. He also conducts clinical trials of new cancer treatments. Park has been a visiting scientist at Genentech, where he performed research on HER2/neu, a protein produced in excessive amounts by some breast cancer cells, and Herceptin, a new treatment that acts as an antibody to HER2/neu.

Rex Yung MD
Rex Yung MD
Chief Medical Advsior

Dr. Yung received his undergraduate degree of BA in Biology cum laude from Harvard

College in Cambridge, Massachusetts. He followed up with matriculation at the University of

California in Los Angeles (UCLA), School of Medicine, and after a year in cardiovascular

research funded by an American Heart Association medical student research fellowship,

returned to clinical training in internal medicine at UCLA. His fellowship training in clinical

Pulmonary and Critical Care medicine was completed at the University of California in San

Francisco’s (UCSF) campuses and research at the UCSF Cardiovascular Research Institute.

Dr. Yung’s first academic appointment was at the University of Southern California where as an

assistant professor of pulmonary & critical care medicine, he was engaged in a broad range of

clinical activities; attending on the consult service, Surgical and Neuro intensive care units,

outpatient subspecialty clinic in Cystic Fibrosis and obstructive lung diseases. His own interest

in lung cancer, advanced diagnostic and interventional bronchoscopy led him to focus on

thoracic oncology. He was recruited to Johns Hopkins University where he served as the

Director of Pulmonary Oncology on the pulmonary service and for some years as the Director of

Bronchoscopy as well.

Nationally and internationally he has been recognized as an expert in the field of

advanced bronchoscopy and thoracic oncology, and have served in leadership positions with

the American College of Chest Physicians, Asia Pacific Society of Respirology, executive

boards of the American Association of Bronchoscopy and International pulmonology, the World

Association of Bronchology and Interventional Pulmonology amongst other national and

international subspecialty medical societies. He has conducted sponsored basic pre-clinical

and clinical research, and have served on various advisory boards of established medical

industry leaders in his field of specialty, such as Olympus, Fujinon, Karl Storz, Boston Scientific,

Philips Imaging, General Electric Imaging. He has also been on the early advisory boards of

medical technology start-ups that have successfully exited, such as PneumRx (British

Technology Group), Asthmatx (Boston Scientific). He was recruited to be the Chief Scientific

Office and subsequently the Chief Medical Officer of Prolung / IONIQ Sciences Inc., working on

biomarkers and Clinical Decision Support in lung cancer early detection. Most recently he has

been appointed the chief medical advisor to Strandsmart Inc, a leader in the field of cancer

liquid biopsies, with novel pathfinder technology to combine high yield Circulating Tumor Cell

(CTC) capture with downstream harvesting for tumor cell expression profiling in advancing non-

invasive cancer diagnosis and directing personalized therapy.

Dr. Yung remains committed to patient care and continues to see and care for patients in

the ambulatory and in-patient clinical settings. From his personal international background of

having been born and raised in East Asia, extensive collaboration with physician scientists

across North America, Europe and East Asia, he has a deep appreciation of the value of

engaging in multidisciplinary and public-private partnerships to advance the medical sciences

and effective delivery of efficacious therapies to the bedside.

Mark Connelly PhD
Mark Connelly PhD
Chief Technology Officer

Mark C. Connelly, Ph.D., is Vice President R&D for StrandSmart. Dr. Connelly has been leading research and development in the field of rare cell detection and diagnostics for over 18 years.

After 14 years with DuPont and Johnson & Johnson, he was named as Vice President, Reagent Development for Immunicon Corporation and Veridex LLC; where he led the development and commercialization of the CellSearch System. He continued as Scientific Director and Site Directorfor Janssen Diagnostics and became the Chief Industrial Operation and Research andDevelopment Officer, US for Menarini Silicon Biosystems. Over the last 32 years, Dr. Connelly has led the development and commercialization of numerous IVD and RUO products and services in the fields of Clinical Chemistry, Retrovirology, Flow Cytometry, Blood Banking, Autoimmunity, Cancer Diagnostics, and Pharmaceutical Drug Development. Dr. Connelly received his B.S. in Biology from Syracuse University, his Ph.D. in Immunochemistry from the University of Rochester, and completed a postdoctoral fellowship in Molecular Parasitology at Michigan State University.

Wes Blakeslee

Wes Blakeslee

General Counsel

Wes Blakeslee is a lawyer, engineer and entrepreneur, and is Principal of Blakeslee, LLC. ( which provides legal and consulting services to universities, university startups, corporations, inventors and entrepreneurs in matters of technology transfer, operations, sponsored research, business formation, moving technology to market, and expert witness services in these and related areas. Blakeslee, LLC provides support to universities regarding policies, particularly intellectual property, conflicts of interest and commitment and sponsored research policies, as well as faculty dispute resolution services. He is a co-founder and General Counsel of StrandSmart, Inc., a startup that licensed and is developing a university invented biomedical technology. 

A former NASA engineer, Wes became a lawyer and after more than 20 years in private law practice joined the General Counsel's office at Johns Hopkins University where he practiced intellectual property and complex business law. In 2006, Wes was appointed Executive Director of Johns Hopkins Technology Transfer, transforming the office into one of the strongest in the US. He is Senator of the Industrial and Professional Advisory Council of the Penn State Department of Engineering Science and Mechanics, and in 2013 received the Penn State Outstanding Engineering Alumni Award the highest honor bestowed by the College of Engineering.

Anula Jayasuriya MD MBA PhD

Anula Jayasuriya MD MBA PhD

Board Director

Anula Jayasuriya is a successful venture capitalist whose background combines deep business, scientific and medical knowledge with broad clinical, industry, entrepreneurial, and investment experience.

Anula founded EXXclaim Capital, an early-stage venture fund focused on catalyzing innovation, entrepreneurship and investment in Women’s Health, and co-founded EILSF, the first Indian fund focusing health care. She sits on several private biotech boards and on the boards of two public companies.  

Previously, Anula was an investor at Skyline Ventures and TVM, VP Business Development at Genomics Collaborative Inc., and Vice President, Global Drug Development at Hoffman-La Roche. 

Anula received her BA from Harvard summa cum laude, and an MD and PhD from Harvard Medical School. She interned in Pediatrics at Boston Children’s Hospital and earned an MBA with distinction from Harvard Business School. 

Mark Myslinski

Mark Myslinski


Mark is a serial life science entrepreneur with multiple exits under his belt, and he is also the only guy to successfully take a liquid biopsy for cancer through the FDA and to the market. Mark was the General Manager of Johnson & Johnson's Veridex unit and the platform is known as CellSearch™ assay. Mark serves as StrandSmart’s Chief Product Officer and is focused on leading the technology transfer process through the product development and approvals phase to market, ready for every physician's office in America. Mark will ensure the manufacturing process is scalable and compliant. Mark’s experience is on the development and commercialization of novel diagnostic tests to the worldwide marketplace.

Ryan Dittamore MBA

Ryan Dittamore MBA

Chief Commercial Advisor

Ryan Dittamore has developed and commercialized multiple oncology products utilized in medicine today. Ryan is the CEO of Cordance Medical, working on enabling precision medicine for neuro-oncology patients. Previously, he was Chief Business Officer of Decipher Biosciences, acquired by Veracyte ($600M), and Chief of Medical Innovation at Epic Sciences, where he led the clinical development, reimbursement, guideline support, and commercial partnering of the AR-V7 CTC test (the first predictive test in prostate cancer). Ryan has also held roles at Roche Diagnostics (Ventana), Genisphere (Code Biotherapeutics), and Bio-Rad. Cumulatively, he has partnered with over 60 biopharma companies, is the author of over 30 peer-reviewed publications, and is the inventor of 12 patents.


Mar 21, 2023
$10k - $1.23M
Common Stock

Maximum Number of Shares Offered subject to adjustment for bonus shares

Most Recent Fiscal Year-End

Prior Fiscal Year-End

Total Assets



Cash & Cash Equivalents



Accounts Receivable



Short-Term Debt



Long-Term Debt



Revenue & Sales



Costs of Goods Sold



Taxes Paid



Net Income



*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.

Voting Rights of Securities Sold in this Offering

Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.

Investment Incentives and Bonuses*

Loyalty Bonus (Previous Investors):

StrandSmart would like to offer you 10% bonus shares


Friends and Family

Invest within the first 48 hours and receive 15% bonus shares

Super Early Bird

Invest within the 72 hours and receive 10% bonus shares

Early Bird Bonus

Invest within the first week and receive 5% bonus shares



1st Tier

5% bonus shares


2nd Tier

10% bonus shares


3rd Tier

15% bonus shares

*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

SmartStrand, Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $4.14 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $414. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investors eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus and the Prior Investor Loyalty Bonus in addition to the aforementioned bonus.

Irregular Use of Proceeds

The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments. Salary payments made to one’s self, a friend or relative.



Our community joins in!

We're excited to see our community come in and invest in StrandSmart! Our Insiders have invested a total of $4,569.62  into the offering to date! We hope you join in as well! 

Please refer to the Company’s offering materials for further information and refer to the Company’s Risk Factors.

Owners bonus
Stack Owner's Bonus & Rewards!

Members get an extra 10% shares in addition to rewards below!


Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into StrandSmart.



Janice Makela

4 months ago

Hi, A test is only as good as the information it gives. Some examples are test like CEA, which might help monitor disease progression but is useless as a screen. Or tests for incurable untreatable diseases. And those are the test that make it to the market. There are several other markers in cancer cells that are useless, because they don't give any info about treatment or prognosis. Though something like HER1/2 can give prognostic and treatment information. What usable information does you test give? You call yourself a liquid biopsy (blood). What does that mean? If you are getting the cancer cells from the blood, does that mean it has already metastasized? Does the tech have any potential in solid tumors that have not metastasized? How far along in your research are you? Do you have any potential markers you are working on? Or is your revenue in the tech you sell to researchers so they can develop markers? Thanks.



David Schrift

4 months ago

Hi, I had a few questions on revenue generation: 1. Can you elaborate on your timeline and pipeline for revenue generation with research/pharmaceutical firms? Do you have firms lined up? Expected range of revenue for each firm? Expected total yearly revenue? Margin expectations? 2. What are the barriers for long term revenue generation with commercialization and how do you plan on addressing them? (What is needed for FDA approval and timeline? How do you plan to get widespread adoption with oncologists? What type of studies do you expect to need to achieve these goals and how long and how expensive do you expect the studies to be?) Thank you! David




Cancel anytime before 48 hours before a rolling close or the offering end date.



We want you to succeed and get the most out of your money by offering rewards and memberships!


Your info is your info. We take pride in keeping it that way!


Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.


@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team



Important Message


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

Investment opportunities posted and accessible through the site are of three types:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.

By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to

StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.